Working... Menu
Trial record 1 of 411 for:    "Muscular dystrophy"
Previous Study | Return to List | Next Study

Stem Cell Therapy in Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02241928
Recruitment Status : Withdrawn
First Posted : September 16, 2014
Last Update Posted : October 25, 2018
Information provided by (Responsible Party):
Neurogen Brain and Spine Institute

Brief Summary:
The purpose of this study was to analyze the effect of autologous bone marrow mononuclear cells in muscular dystrophy.

Condition or disease Intervention/treatment Phase
Muscular Dystrophy Biological: Stem Cell Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Role of Autologous Mononuclear Cell Therapy in Muscular Dystrophy
Study Start Date : January 2009
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : May 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Stem Cell
Bone marrow mononuclear cell transplantation
Biological: Stem Cell
Intrathecal Autologous bone marrow mononuclear cell transplantation

Primary Outcome Measures :
  1. Manual Muscle Testing [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Months to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age group of 6 months and above
  • muscular dystrophy diagnosed on the basis of clinical presentation

Exclusion Criteria:

  • presence of respiratory distress
  • presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus
  • malignancies
  • acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction < 30%
  • pregnancy or breastfeeding

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02241928

Layout table for location information
Neurogen brain and spine institute
Navi Mumbai, Maharashtra, India, 400706
Sponsors and Collaborators
Neurogen Brain and Spine Institute

Layout table for additonal information
Responsible Party: Neurogen Brain and Spine Institute Identifier: NCT02241928     History of Changes
Other Study ID Numbers: NGBSI-14
First Posted: September 16, 2014    Key Record Dates
Last Update Posted: October 25, 2018
Last Verified: October 2018

Keywords provided by Neurogen Brain and Spine Institute:
Muscular Dystrophy
Autologous Mononuclear cell therapy
Stem Cell

Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn